培美曲塞联合顺铂二线治疗晚期非小细胞肺癌36例临床观察

目的 观察培美曲塞联合顺铂二线治疗晚期非小细胞肺癌的近期疗效及毒副反应。方法对36例初治失败的晚期非小细胞肺癌给予培美曲塞联合顺铂化疗，培美曲塞500mg／m2,dl静脉滴注；顺铂75mg／m2,静脉滴注，分1-3d；21d为1个周期。结果36例患者有效率为27．77％，其中完全缓解0例，部分缓解10例，稳定15例，进展11例，疾病控制率为69．44％，主要不良反应为胃肠道反应、皮疹及骨髓抑制，但均可耐受，无化疗相关性死亡。结论 培美曲塞联合顺铂二线治疗晚期非小细胞肺癌有较好的疗效，毒副反应较轻可以耐受。

Clinical observation of the effect of pemetrexed combined with cisplatin on 36 patients with advanced non small cell lung cancer as a second-line regimen

Objective To evaluate the efficacy and toxicity of the multitargeted antifolate pemetrexed in patients with advanced non small cell lung cancer.Methods Thirty-six patients with advanced NSCLC,who had failed in previous chemotherapy,were diagnosed by histology and/or cytology.The salvage chemotherapy strategy was pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2.Pemetrexed was given on day 1 and cisplatin was given on day 1～3 every 3 weeks.The patients who received chemotherapy two or more cyc1es were evaluated.Results There was no case with complete response,only 10 cases showed partial response,15 cases had stable disease and 11 cases got progressive disease.The responsive rate was 27.77%(10/36),and the disease controlling rate was 69.44%(25/36).The main side effects were gastrointestinal response and hematologic toxicities,but they were tolerable,and there was no death related with treatment.Conclusion Advanced NSCLC patients previously treated can benefit from pemetrexed chemotherapy with tolerable adverse events as a second-line regimen.